NanO2 in Large VessEL Occlusion Stroke (NOVEL)

A phase 2 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 172 participants.

Also called NCT06821347

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 172 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06821347
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United Kingdom (from the registry)
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT06821347. Randomized; double masking; primary purpose treatment. Start 2025-05-01 (anticipated); primary completion 2026-07-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
NanO2 in Large VessEL Occlusion Stroke (NOVEL)
Acronym
NOVEL
Condition
Stroke Acute
Intervention (Drug)
NanO2TM
Intervention (Other)
Sodium Chloride 0.9% Intravenous
Lead sponsor
NHS Greater Glasgow and Clyde (class: other)
Collaborator
University of Glasgow (class: other)
Collaborator
NuvOx LLC (class: industry)

Record details

Record id
cardio:ct-nct06821347
Content hash
3707c23a7437b1264d35fbdfbf2c7962369866b70f21534ba63cbcf80227c421